<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188668</url>
  </required_header>
  <id_info>
    <org_study_id>B2061026</org_study_id>
    <secondary_id>3151A1-1207</secondary_id>
    <nct_id>NCT01188668</nct_id>
  </id_info>
  <brief_title>Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects</brief_title>
  <official_title>An Open-Label, 2-Period Sequential Drug Interaction Study To Evaluate The Effect Of A 100 Mg Dose Of Desvenlafaxine SR On The Pharmacokinetics Of Aripiprazole When Coadministered In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine
      Sustained Release (SR) on the pharmacokinetics of Aripiprazole when coadministered to healthy
      adult subjects. This study will also evaluate the safety and tolerability of Desvenlafaxine
      SR and Aripiprazole when coadministered to healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aripiprazole Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞); measured as nanograms multiplied by hours divided by milliliters (ng*hr/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aripiprazole Maximum Observed Plasma Concentration (Cmax) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
    <description>Cmax measured as nanograms per milliliters (ng/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aripiprazole Time for Cmax (Tmax) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
    <description>Time for maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aripiprazole Terminal Half-life (t 1/2) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
    <description>Terminal half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aripiprazole Apparent Clearance (CL/F) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aripiprazole Apparent Volume of Distribution (Vz/F) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
    <description>Calculated as Dose / (AUCinf * kel); where kel=terminal phase rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydro-aripiprazole (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
    <description>Dehydro-aripiprazole is a metabolite of Aripiprazole. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydro-aripiprazole (Metabolite) Maximum Observed Plasma Concentration (Cmax) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydro-aripiprazole (Metabolite) Time for Cmax (Tmax) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
    <description>Time for maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydro-aripiprazole (Metabolite) Terminal Half-life (t 1/2) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
    <description>Terminal half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydro-aripiprazole (Metabolite) Apparent Clearance (CL/F) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydro-aripiprazole (Metabolite) Apparent Volume of Distribution (Vz/F) Following Aripiprazole Alone and When Coadministered With DVS SR</measure>
    <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Aripiprazole Concentration Versus Time Summary: Aripiprazole 5mg, DVS SR 100 mg + Aripiprazole 5 mg</measure>
    <time_frame>Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing</time_frame>
    <description>Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Dehydro-aripiprazole (Metabolite) Concentration Versus Time Summary: Aripiprazole 5mg, DVS SR 100 mg, Aripiprazole 5 mg</measure>
    <time_frame>Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing</time_frame>
    <description>Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Cytochrome P-450 CYP2D6</condition>
  <condition>CYP3A4 Protein, Human</condition>
  <arm_group>
    <arm_group_label>Aripiprazole + Desvenlafaxine SR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Period 1-Aripiprazole 5mg on study day 1.</description>
    <arm_group_label>Aripiprazole + Desvenlafaxine SR</arm_group_label>
    <other_name>DVS-233; Pristiq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole + desvenlafaxine succinate sustained release</intervention_name>
    <description>Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.</description>
    <arm_group_label>Aripiprazole + Desvenlafaxine SR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 18 and 55 years

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight &gt;50 kg (110 lbs)

          -  Nonsmoker or smoker of fewer than 5 cigarettes per day as determined by history

          -  An informed consent document signed and dated by the subject

        Exclusion Criteria:

          -  History of significant blood, kidney, endocrine, lung, gastrointestinal, heart, liver,
             psychiatric, neurologic, or allergic disease

          -  History of seizure disorder

          -  Presence or history of glaucoma or increased intraocular pressure

          -  Allergy to or unable to tolerate aripiprazole, desvenlafaxine, or venlafaxine

          -  History of substance abuse within 1 year of study

          -  A positive urine drug screen

          -  Treatment with an investigational drug within 30 days

          -  Consumption of grapefruit or grapefruit related citrus fruits

          -  12 lead ECG demonstrating QTc &gt;450 msec at screening

          -  Pregnant or nursing females

          -  Use of prescription or nonprescription drugs and dietary supplements

          -  History of sensitivity to heparin or heparin induced thrombocytopenia

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2061026&amp;StudyName=Open%20Label%20Drug%20Interaction%20Study%20Evaluating%20Desvenlafaxine%20Succinate%20Sustained%20Release%20%28DVS%20SR%29%20100mg%20On%20The%20Pharmacokinetics%20Of%20Aripip</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <results_first_submitted>September 9, 2011</results_first_submitted>
  <results_first_submitted_qc>September 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2011</results_first_posted>
  <last_update_submitted>November 1, 2011</last_update_submitted>
  <last_update_submitted_qc>November 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <keyword>safety and tolerability</keyword>
  <keyword>genetic testing</keyword>
  <keyword>CYP 2D6 and CYP 3A4</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aripiprazole 5 mg, Aripiprazole 5 mg + DVS SR 100 mg</title>
          <description>Aripiprazole (ARIP) as a single oral dose of 5 milligrams (mg) Period 1 / Day 1. Desvenlafaxine sustained release (DVS SR) as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: ARIP Alone</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: Coadministration ARIP + DVS SR</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole 5 mg, Aripiprazole 5 mg + DVS SR 100 mg</title>
          <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1. DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aripiprazole Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <description>Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞); measured as nanograms multiplied by hours divided by milliliters (ng*hr/mL).</description>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
        <population>Pharmacokinetic (PK) parameter analysis population: all randomized and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period. N=Number of participants contributing to the mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Aripiprazole Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <description>Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞); measured as nanograms multiplied by hours divided by milliliters (ng*hr/mL).</description>
          <population>Pharmacokinetic (PK) parameter analysis population: all randomized and treated participants who had at least 1 of the PK parameters of primary interest in at least 1 treatment period. N=Number of participants contributing to the mean.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1494" spread="699.98"/>
                    <measurement group_id="O2" value="1604" spread="561.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DVS SR 100 mg + Aripiprazole 5 mg (test) versus Aripiprazole 5 mg (reference)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of adjusted means</param_type>
            <param_value>105.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.39</ci_lower_limit>
            <ci_upper_limit>110.76</ci_upper_limit>
            <estimate_desc>Values have been back-transformed from the log scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aripiprazole Maximum Observed Plasma Concentration (Cmax) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <description>Cmax measured as nanograms per milliliters (ng/mL).</description>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
        <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Aripiprazole Maximum Observed Plasma Concentration (Cmax) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <description>Cmax measured as nanograms per milliliters (ng/mL).</description>
          <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.66" spread="7.6031"/>
                    <measurement group_id="O2" value="24.69" spread="7.4186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DVS SR 100 mg + Aripiprazole 5 mg (test) versus Aripiprazole 5 mg (reference)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of adjusted means</param_type>
            <param_value>101.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.94</ci_lower_limit>
            <ci_upper_limit>109.87</ci_upper_limit>
            <estimate_desc>Values have been back-transformed from the log scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aripiprazole Time for Cmax (Tmax) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <description>Time for maximum observed plasma concentration.</description>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
        <population>PK parameter analysis population. N=Number of participants contributing to the median.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Aripiprazole Time for Cmax (Tmax) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <description>Time for maximum observed plasma concentration.</description>
          <population>PK parameter analysis population. N=Number of participants contributing to the median.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="2.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aripiprazole Terminal Half-life (t 1/2) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <description>Terminal half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
        <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Aripiprazole Terminal Half-life (t 1/2) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <description>Terminal half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.17" spread="22.191"/>
                    <measurement group_id="O2" value="84.18" spread="20.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aripiprazole Apparent Clearance (CL/F) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).</description>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
        <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Aripiprazole Apparent Clearance (CL/F) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).</description>
          <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.76" spread="25.345"/>
                    <measurement group_id="O2" value="51.92" spread="19.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aripiprazole Apparent Volume of Distribution (Vz/F) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <description>Calculated as Dose / (AUCinf * kel); where kel=terminal phase rate constant.</description>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
        <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Aripiprazole Apparent Volume of Distribution (Vz/F) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <description>Calculated as Dose / (AUCinf * kel); where kel=terminal phase rate constant.</description>
          <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397.3" spread="129.28"/>
                    <measurement group_id="O2" value="368.1" spread="102.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dehydro-aripiprazole (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <description>Dehydro-aripiprazole is a metabolite of Aripiprazole. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
        <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Dehydro-aripiprazole (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <description>Dehydro-aripiprazole is a metabolite of Aripiprazole. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
          <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="695.9" spread="151.95"/>
                    <measurement group_id="O2" value="685.8" spread="148.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DVS SR 100 mg + Aripiprazole 5 mg (test) versus Aripiprazole 5 mg (reference)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of adjusted means</param_type>
            <param_value>102.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.21</ci_lower_limit>
            <ci_upper_limit>112.46</ci_upper_limit>
            <estimate_desc>Values have been back-transformed from the log scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dehydro-aripiprazole (Metabolite) Maximum Observed Plasma Concentration (Cmax) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing</time_frame>
        <population>PK parameter analysis population. N=number of participants contributing to the mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Dehydro-aripiprazole (Metabolite) Maximum Observed Plasma Concentration (Cmax) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <population>PK parameter analysis population. N=number of participants contributing to the mean.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.007" spread="1.0889"/>
                    <measurement group_id="O2" value="3.185" spread="1.0127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DVS SR 100 mg + Aripiprazole 5 mg (test) versus Aripiprazole 5 mg (reference)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of adjusted means</param_type>
            <param_value>106.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.97</ci_lower_limit>
            <ci_upper_limit>111.85</ci_upper_limit>
            <estimate_desc>Values have been back-transformed from the log scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dehydro-aripiprazole (Metabolite) Time for Cmax (Tmax) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <description>Time for maximum observed plasma concentration.</description>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
        <population>PK parameter analysis population. N=number of participants contributing to the mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Dehydro-aripiprazole (Metabolite) Time for Cmax (Tmax) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <description>Time for maximum observed plasma concentration.</description>
          <population>PK parameter analysis population. N=number of participants contributing to the mean.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9" lower_limit="23.9" upper_limit="120"/>
                    <measurement group_id="O2" value="71.9" lower_limit="23.9" upper_limit="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dehydro-aripiprazole (Metabolite) Terminal Half-life (t 1/2) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <description>Terminal half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
        <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Dehydro-aripiprazole (Metabolite) Terminal Half-life (t 1/2) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <description>Terminal half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>PK parameter analysis population. N=Number of participants contributing to the mean.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.78" spread="16.588"/>
                    <measurement group_id="O2" value="94.27" spread="16.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dehydro-aripiprazole (Metabolite) Apparent Clearance (CL/F) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf).</description>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
        <population>PK parameter analysis population. Data was insufficient for analysis; not analyzable.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Dehydro-aripiprazole (Metabolite) Apparent Clearance (CL/F) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf).</description>
          <population>PK parameter analysis population. Data was insufficient for analysis; not analyzable.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dehydro-aripiprazole (Metabolite) Apparent Volume of Distribution (Vz/F) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
        <time_frame>Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing; Period 2 / Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours after dosing; also 0 hour Period 2 / Day 8, 9, 10, 12, 14, 16, 18, and Day 20</time_frame>
        <population>PK parameter analysis population. Data was insufficient for analysis; not analyzable.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Dehydro-aripiprazole (Metabolite) Apparent Volume of Distribution (Vz/F) Following Aripiprazole Alone and When Coadministered With DVS SR</title>
          <population>PK parameter analysis population. Data was insufficient for analysis; not analyzable.</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Aripiprazole Concentration Versus Time Summary: Aripiprazole 5mg, DVS SR 100 mg + Aripiprazole 5 mg</title>
        <description>Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.</description>
        <time_frame>Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing</time_frame>
        <population>PK concentration analysis population: all randomized and treated participants who had at least 1 concentration in at least 1 treatment period. Period 2 / Day 1 = Day 1 of Aripiprazole dosing (Period 2 / Day 7) within the DVS SR, Aripiprazole coadministration dosing period.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Aripiprazole Concentration Versus Time Summary: Aripiprazole 5mg, DVS SR 100 mg + Aripiprazole 5 mg</title>
          <description>Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.</description>
          <population>PK concentration analysis population: all randomized and treated participants who had at least 1 concentration in at least 1 treatment period. Period 2 / Day 1 = Day 1 of Aripiprazole dosing (Period 2 / Day 7) within the DVS SR, Aripiprazole coadministration dosing period.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O2" value="0.1290" lower_limit="0.000" upper_limit="0.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4800" lower_limit="0.000" upper_limit="6.65"/>
                    <measurement group_id="O2" value="1.220" lower_limit="0.000" upper_limit="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.69" lower_limit="0.000" upper_limit="26.9"/>
                    <measurement group_id="O2" value="9.545" lower_limit="0.167" upper_limit="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.40" lower_limit="1.07" upper_limit="46.7"/>
                    <measurement group_id="O2" value="21.70" lower_limit="0.824" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.75" lower_limit="3.01" upper_limit="37.2"/>
                    <measurement group_id="O2" value="24.40" lower_limit="8.27" upper_limit="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.35" lower_limit="5.59" upper_limit="35.1"/>
                    <measurement group_id="O2" value="25.40" lower_limit="8.85" upper_limit="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.95" lower_limit="9.96" upper_limit="27.9"/>
                    <measurement group_id="O2" value="20.70" lower_limit="7.22" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.65" lower_limit="8.39" upper_limit="23.7"/>
                    <measurement group_id="O2" value="18.00" lower_limit="7.24" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.65" lower_limit="6.53" upper_limit="23.7"/>
                    <measurement group_id="O2" value="13.80" lower_limit="6.46" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.50" lower_limit="5.73" upper_limit="18.2"/>
                    <measurement group_id="O2" value="12.50" lower_limit="5.84" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.70" lower_limit="5.35" upper_limit="18.1"/>
                    <measurement group_id="O2" value="12.20" lower_limit="5.47" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.310" lower_limit="3.88" upper_limit="14.2"/>
                    <measurement group_id="O2" value="8.940" lower_limit="4.64" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.255" lower_limit="2.46" upper_limit="11.6"/>
                    <measurement group_id="O2" value="6.870" lower_limit="3.36" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.680" lower_limit="1.63" upper_limit="10.1"/>
                    <measurement group_id="O2" value="4.000" lower_limit="1.88" upper_limit="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.390" lower_limit="0.926" upper_limit="16.3"/>
                    <measurement group_id="O2" value="2.720" lower_limit="0.872" upper_limit="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>216 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.730" lower_limit="0.491" upper_limit="13.4"/>
                    <measurement group_id="O2" value="1.960" lower_limit="0.457" upper_limit="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>264 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.080" lower_limit="0.337" upper_limit="4.41"/>
                    <measurement group_id="O2" value="1.340" lower_limit="0.237" upper_limit="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>312 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8040" lower_limit="0.202" upper_limit="3.99"/>
                    <measurement group_id="O2" value="1.010" lower_limit="0.128" upper_limit="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Dehydro-aripiprazole (Metabolite) Concentration Versus Time Summary: Aripiprazole 5mg, DVS SR 100 mg, Aripiprazole 5 mg</title>
        <description>Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.</description>
        <time_frame>Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 120, 168, 216, 264, and 312 hours after dosing</time_frame>
        <population>PK concentration analysis population: all randomized and treated participants who had at least 1 concentration in at least 1 treatment period. Period 2 / Day 1 = Day 1 of Aripiprazole dosing (Period 2 / Day 7) within the DVS SR, Aripiprazole coadministration dosing period.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole 5 mg (Period 1)</title>
            <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
            <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state) and Day 7 though 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Dehydro-aripiprazole (Metabolite) Concentration Versus Time Summary: Aripiprazole 5mg, DVS SR 100 mg, Aripiprazole 5 mg</title>
          <description>Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.</description>
          <population>PK concentration analysis population: all randomized and treated participants who had at least 1 concentration in at least 1 treatment period. Period 2 / Day 1 = Day 1 of Aripiprazole dosing (Period 2 / Day 7) within the DVS SR, Aripiprazole coadministration dosing period.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O2" value="0.1640" lower_limit="0.000" upper_limit="0.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.0000" upper_limit="0.138"/>
                    <measurement group_id="O2" value="0.2120" lower_limit="0.000" upper_limit="0.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2740" lower_limit="0.000" upper_limit="1.38"/>
                    <measurement group_id="O2" value="0.5965" lower_limit="0.000" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9470" lower_limit="0.000" upper_limit="4.29"/>
                    <measurement group_id="O2" value="1.240" lower_limit="0.132" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.260" lower_limit="0.115" upper_limit="5.55"/>
                    <measurement group_id="O2" value="1.660" lower_limit="0.473" upper_limit="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.495" lower_limit="0.277" upper_limit="5.38"/>
                    <measurement group_id="O2" value="1.880" lower_limit="0.791" upper_limit="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.650" lower_limit="0.453" upper_limit="5.57"/>
                    <measurement group_id="O2" value="1.910" lower_limit="0.686" upper_limit="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.780" lower_limit="0.689" upper_limit="5.80"/>
                    <measurement group_id="O2" value="1.910" lower_limit="0.686" upper_limit="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.845" lower_limit="0.748" upper_limit="5.35"/>
                    <measurement group_id="O2" value="1.950" lower_limit="0.654" upper_limit="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.010" lower_limit="0.819" upper_limit="5.16"/>
                    <measurement group_id="O2" value="1.970" lower_limit="0.695" upper_limit="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.520" lower_limit="1.01" upper_limit="6.29"/>
                    <measurement group_id="O2" value="2.550" lower_limit="0.952" upper_limit="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.135" lower_limit="1.26" upper_limit="5.79"/>
                    <measurement group_id="O2" value="3.160" lower_limit="1.00" upper_limit="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.935" lower_limit="1.31" upper_limit="4.61"/>
                    <measurement group_id="O2" value="3.020" lower_limit="1.06" upper_limit="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.440" lower_limit="1.25" upper_limit="4.16"/>
                    <measurement group_id="O2" value="2.360" lower_limit="1.14" upper_limit="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.920" lower_limit="0.996" upper_limit="3.76"/>
                    <measurement group_id="O2" value="1.980" lower_limit="1.09" upper_limit="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>216 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.570" lower_limit="0.650" upper_limit="3.17"/>
                    <measurement group_id="O2" value="1.460" lower_limit="0.744" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>264 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.080" lower_limit="0.429" upper_limit="3.13"/>
                    <measurement group_id="O2" value="1.130" lower_limit="0.454" upper_limit="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>312 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8660" lower_limit="0.248" upper_limit="2.85"/>
                    <measurement group_id="O2" value="0.9680" lower_limit="0.252" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Day 27 (follow-up telephone visit)</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study. Participants are counted for each treatment sequence.</desc>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole 5 mg (Period 1)</title>
          <description>Aripiprazole as a single oral dose of 5 mg Period 1 / Day 1.</description>
        </group>
        <group group_id="E2">
          <title>DVS SR 100 mg (Period 2)</title>
          <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 1 through Day 6 (steady state).</description>
        </group>
        <group group_id="E3">
          <title>Aripiprazole 5 mg + DVS SR 100 mg (Period 2)</title>
          <description>DVS SR as a single oral dose of 100 mg Period 2 / Day 7 though Day 19. Aripiprazole as a single oral dose of 5 mg coadministered with the DVS SR dose on Period 2 / Day 7.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Salivary gland pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Attention deficit / hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

